DESIO, Italy – Low folate concentrations have been associated with both an increased incidence of depression and an inadequate response to treatment. Folate deficiency is common among depressed people, especially those who don’t respond to antidepressants: major depressive disorder (MDD) currently ranks as the fourth leading disease burden worldwide and is expected to become the second global disease burden in 2020. (Hyman 2006 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036555/#B1)

Depression is among the top public health concerns worldwide, causing significant disability and disease burden (Whiteford Lancet 2013). Only just in the United States, a total of 200 billion is spent annually on depression, 2 eclipsing the totals spent on cancer and diabetes. In 2012, it was estimated that 16 million people were living with depression in the United States. (1)

Estimates suggest that as many as 12% of men and 25% of women will experience a clinically significant depressive episode in their lives. Of those being treated, approximately 50% will experience a clinically meaningful response to treatment and even fewer will achieve remission (ie, absence of symptoms and return to normal functioning), despite the availability and wide use of several pharmacologic agents. (2)

The metabolically active form of folate Quatrefolic^®, (6S)-5-MTHF or L-methylfolate, sustains brain functions and the production of neurotransmitters through its role in one carbon metabolism, network of interrelated biochemical reactions that involves the transfer of one carbon methyl groups from one compound to another. (3)

When we look at the methylation cycle its clear that optimum methylation is required to produce neurotransmitters like serotonin and dopamine.

In the one carbon metabolism the remethylation of homocysteine produces methionine, the precursor of S-adenosylmethionine (SAMe) that is the primary methyl group donor in the brain.
SAMe has a key role in mood and cognitive functions because increases levels of dopamine and norepinephrine and accelerate the production, uptake, and re-release of serotonin (4). Adomet^® is the commercially stable form of SAMe for nutraceutical applications.

Perturbations of one carbon metabolism, due to low levels of 5-MTHF, critically contribute in decreasing the availability of SAMe and increase the levels of circulating homocysteine, a recognized risk factor for cognitive decline and incident dementia. As a matter of fact low SAMe concentrations have been observed in the cerebrospinal fluid of depressed persons. (3)

Recent evidence has emphasized how partial- or non-responders to antidepressant drugs may be gravely folate deficient, caused by a polymorphism of the enzyme methylenetetrahydrofolate reductase (MTHFR), which is quite common among patients with depression. These individuals have impaired capacity to convert food folate/folic acid into the metabolic active form, the 5-MTHF or L-methylfolate. Up to 70% of patients with depression test positive for the polymorphism rendering folic acid supplements ineffective for helping in depression.(5)

As a matter of fact, the common approach to raise folate levels by supplementation of the synthetic and man-made folic acid, could be ineffective. Folic acid is the synthetic form of folate and is not biologically active. The body must convert FA into 5-MTHF (L-methylfolate) before the brain can manufacture serotonin, norepinephrine, and dopamine to alleviate depression. People taking FA may still be gravely folate deficient because of the inability of a part of world’s population to assimilate and metabolize folate to 5-MTHF (5,6)

MTHFR polymorphisms are estimated to occur in up to 57% of the population. These subjects need the metabolically active form of folate, the 5-MTHF, the only folate which does not need to be metabolized and is immediately available in the brain to support SAMe release and consequently the production of neurotransmitters. (6,7)

Because patients with low serum folate and hyperhomocysteinemia also have low SAMe levels, it has been suggested that oral supplementation of folate in the form of 5-MTHF (L-Methylfolate) and SAMe may alleviate or prevent depression, reducing also the high levels of homocysteine.
As reported by Papakostas in 2012 supplementation with SAMe, as well as with (6S)-5-MTHF, appears to be efficacious and useful to enhance mood and may be considered an useful adjuvant strategy to increase drug treatment efficacy.

Gnosis’ Quatrefolic^®, the patented glucosamine salt of the (6S)-5-MTHF, provides folate in the already biologically active form of 5-methyltetrahydrofolate, without any kind of metabolization. 5-MTHF can reach the systemic circulation and cross the blood-brain barrier, and enter straight the brain cell, for direct utilization in the folate cycle.

Gnosis’ Adomet^®, the commercially stable form of SAMe, results from more than 30 years of knowledge of this active and more than 10 patents, ranging from manufacturing processes and stabilization of salts to the production of innovative forms of oral dosage.

1 – Ionescu 2015 Dialogues Clin Neurosci
2 – Shelton 2006 Primary Psychiatry. 2006;13(4):73-82
3 – Bottiglieri 2002 Am J Clin Nutr
4 – Mischoulon 2002 Am J Clin Nutr
5 – Kelly 2004 J Psychopharmacol
6 – Van der Put 1998 Am. J. Hum.
7 – Genet Meshkin 2007 Drug Metab Lett
8 – Papakostas 2012 Can J Psychiatry.

The ability of the human body to quickly recognise and eradicate invading pathogens is essential for controlling infections and preventing infectious disease. Nature has therefore armed the body with a highly efficient defence apparatus: the immune system.

The immune system normally has the upper hand on opportunistic microorganisms; thanks mainly to the evolutionary conserved innate immune defence which fights back more than 99 % of all the microbial threats the body is exposed to every day.

Beta-1,3/1,6- glucan from baker’s yeast (Saccharomyces cerevisiae) is a biological response modifier which through direct interaction with cells of the innate immune system, safely primes the immune system to respond quickly and adequately to infectious challenge. This feature has, over the last 20 years, made beta-1,3/1,6-glucan from baker’s yeast attractive as a dietary supplement and as a functional food ingredient. Here, we explain the current understanding of the mode of action of beta-1,3/1,6-glucan on the immune system.

Download the whitepaper here

Now you can find a clear chart that explains the folate metabolic pathway, from folic acid to active 5-methyltetrahydrofolate (5-MTHF)! As a matter of fact folic acid must be converted to an active form before it is used by the body.

Step by step, discover the benefits that Gnosis’ Quatrefolic® offers VS Folic Acid!

Quatrefolic® is the glucosamine salt of (6S)-5-methyltetrahydrofolate and is structurally analogous to the reduced and active form of folic acid, so Quatrefolic® completely bypasses the conversion step and delivers a “finished” folate the body can immediately use without any kind of metabolization.

Download the infographic

Impaired Folic Acid Metabolism and MTHFR Polymorphism

Methylenetetrahydrofolate reductase (MTHFR) is one of the most important enzymes in human physiology, deficiencies in production or function of this enzyme have been associated with increased risk of chronic disease states. Some individuals, due to their unique genetic patterns and expression, have polymorphic forms of this enzyme and do not produce adequate or effective MTHFR.

MTHFR converts folic acid/ food folates into the activated form, (6S)-5-MTHF or 5-methyltetrahydrofolate.
Genetic variations of this enzyme may impair MTHFR activity from 55% to 70% efficiency compared to a normal MTHFR enzyme. MTHFR polymorphisms are estimated to occur in up to 40% of the world population (1, 2, 3).

Based on the high prevalence of MTHFR genetic polymorphisms in the general population and concerns about reduced enzymatic activity, the worldwide scientific community is focusing newer research in this area, suggesting even more to replace folic acid supplementation with the biological active form (6S)-5-methyltetrahydrofolate, such as Quatrefolic®, for preventing folate-related pathology.

The debate about folic acid vs (6S)-5-MTHF also extends to consumers which are even more aware about the deep implications of MTHFR polymorphism in supporting their health. Consumers are also concerned about the potential clinical implications and adverse effects of high dose of folic acid assumed unconsciously due to uncontrolled consumption fortified foods.

Several studies have reported an increase in serum of unmetabolized folic acid (UMFA) levels since the implementation of folic acid fortification. A study published in 2014 clearly showed that 86% of folic acid in the hepatic portal vein is unmetabolized, whilst almost all of the natural folate was converted correctly (3,4).
Variability in the presence or persistence of UMFA in the population suggests that it may be accumulated in the blood as a consequence of different conditions, such as the impairment, and/or the slackness of the folic acid reduction pathway to the 5-methyltetrahydrofolate (genetic polymorphism), and the overdosing effect due to uncontrolled folic acid intake

Quality seal affirms the safety of Kaneka’s patented high purity ingredient

Brussels (Belgium) – Kaneka Pharma Europe unveiled a globally unified logo for its worldwide registered and patented ingredient Kaneka Ubiquinol™. Used as a nutritional supplement, the directly active form of coenzyme Q10 is crucial for energy production in the human body, as well as being a powerful antioxidant. Kaneka is introducing its new brand logo in response to the growing popularity of the ingredient, which is increasingly being imitated by fake products of inferior quality. The new global brand logo for Kaneka Ubiquinol™ guarantees the superior provenance of its ingredient to manufacturers and customers alike.     

Renowned for its unique and patented production processes, Kaneka places great emphasis on the development of natural and scientifically-backed ingredients. Ubiquinol has been well known for a long time, but it is challenging to manufacture on an industrial scale because it is easily oxidized. After more than ten years of research and process development, however, the Japanese company succeeded in devising a patented yeast-fermentation technique, and it is now the only supplier of the world’s first stable and bio-identical Ubiquinol. The micronutrient can support the body’s immune defences, counteract fatigue, stress and the visible signs of aging, and help to prevent cardiovascular diseases. Its high bioavailability enables the vitamin-like supplement to be taken up by the body more quickly and efficiently than conventional coenzyme Q10. Kaneka Ubiquinol^™ can be used in a variety of applications, including soft gel capsules, pellets and sticks. Filip Van hulle, Senior Marketing Manager at Kaneka, states: “As our manufacturing partners now can brand their products with the new logo, together we can give customers proof that they are buying a safe and traceable Ubiquinol product of premium quality.”

After the grant of the health claim of Gnosis’ Superesse®, the enriched natural yeast with S-Adenosylmethionine (SAMe), by The Japanese Ministry of Health, Labour and Welfare (MHLW) for the “Improvement for the joint wrongness”, new possibilities are available for strict regulated countries, were S-Adenosylmethionine “as is” was not allowed to be used in nutritional supplements first.

The recognition of the health claim on joint follows the publication of a placebo-controlled double-blind randomized clinical trial in healthy male and female adults, aged 40 to < 59 years, who had chronic discomfort in the knee joint and that had persisted for at least 3 months at the time of enrollment with no history of OA. (N. Yamanaka, et al. “The effects of SAM-e yeast to improve the discomfort of knee in healthy adults” Jpn Pharmacol Ther vol.43 no. 4 2015).

Japan is thought leader in the manufacture and use of “Foods with Health Claims” – the preferred term for dietary supplements and natural nutraceuticals. The health-conscious Japanese have long embraced the benefits from nutraceuticals, and the country ranked third in per capita spend on nutraceuticals in 2014 according to World Health Organization (WHO) data, while others place Japan as the second largest individual consumer of nutraceuticals (behind the U.S.).

The effectiveness of SAMe Superesse® was evaluated through a symptom scores on a questionnaire, which takes the format of a scale from 0 to 10, or a VAS (visual analogue scale). The questionnaire items used the “Locomotive Syndrome Risk Test”) presented by the Japanese Orthopedic Association as a reference, and the subjective symptoms of the 10 items set were the targets for evaluation.

The use of Saccharomyces cerevisiae (the primary yeast used in baking and brewing) is very known because it represents an excellent source of several nutritional compounds such as vitamins and proteins, fruitful for human health. As ‘nutritional yeasts’ it is used in the form of dried and inactive yeasts and may contains also other important substances, as happens in Superesse® product, SAMe. These natural components are available in the native structure, and they are biologically active.

The product has been designed by Gnosis combining the expertise in biofermentation processes and the knowledge as the leading global manufacturer of SAMe to obtain a new ingredient for the food market. SupereSSe® activity derives from the natural content of (S,S) SAM-e stereoisomer contained in the dried cells. This metabolite is present in all living cells and plays a central role in cellular biochemistry centered in one carbon metabolism cycle. SAMe is involved in over 35 methylation reactions related to DNA, proteins, lipids and hormones, impacting cellular function in countless ways, among them, neurotransmitter synthesis and membrane function. (S,S) is the biologically active form of SAMe that produces healthy benefits, supporting joint functions, but also mood and emotional well-being, working as a liver protector as well.

Superesse® guarantees stable form without addition of stabilizing agents.  It is highly flavorful and simple to administer (direct administration of product in suitable nutraceutical forms especially capsules, tablets and sachets). It can be easy combined with other ingredients and excipients.

Know more about SupereSSe^®

For more information see the Gnosis page

Label More Clearly Identifies Setria® as the Antioxidant Inside*

New York, NY –  NOW® Foods has released new-look bottles for its 250mg and 500mg Setria® Glutathione vegetarian capsules.

The new labels better identify Setria® Glutathione as the main ingredient in the antioxidant dietary supplements. Combined with milk thistle extract and Alpha Lipoic Acid™, Setria® provides potent antioxidant protection at the cellular level.* Setria® Glutathione, a premium brand of glutathione – called nature’s “master antioxidant” – replenishes the body’s stores while also protecting cells from oxidative stress and harmful toxins associated with free radicals.*

Setria® is a clinically studied and patented form of L-Glutathione that has been shown to increase body stores of glutathione.* Setria replenishes the body’s stores of glutathione, while also protecting cells from oxidative stress, harmful toxins and free radicals.*

For more information about NOW® Glutathione, visit NOW Foods.

About NOW Foods
Founded by Elwood Richard in 1968 on the belief that natural is better, NOW has grown from a small family operation into one of the most highly respected manufacturers in the natural products industry. Still a family-owned company today, NOW provides customers with a comprehensive approach to wellness by offering more than 1,400 dietary supplements, foods, sports nutrition and personal care products. NOW is committed to offering safe, affordable products of the highest quality, and is a highly regarded advocate in the natural products industry. Its state-of-the-art manufacturing facility in Bloomingdale, Ill., has been GMP (Good Manufacturing Practice)-certified since 2000 and its in-house laboratory capabilities are among the best in the industry. The company has over 1500 employees, and its products are sold in more than 70 countries. After more than 45 years in the natural products industry, NOW remains committed to its original mission – to provide value in products and services that empower people to lead healthier lives.

Learn more at NOWFoods.com.

About Setria Glutathione
Setria® Glutathione, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of glutathione that, when taken orally1, has been shown to replenish the body’s reserves, which may be depleted as a result of poor lifestyle choices, stress or natural aging. Called the “master antioxidant,” glutathione helps protect cells in the body from the damaging effects of oxidative stress and toxins. Setria glutathione is manufactured through a patented fermentation process to yield high purity and high quality, is vegetarian and allergen-free. For more information about Setria glutathione, visit the Setria Glutathione page.

References
1 Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. May 2014: 1436-6207. doi: 10.1007/s00394-014-0706-z

** Setria® is a registered trademark of Kyowa Hakko Bio Co., Ltd.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Lumistor® L-Hydroxyproline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine® L-Alanyl-L-Glutamine.

It has been well established that phytosterols lower total and LDL cholesterol. However, due to their insolubility in water and lipids, phytosterols incorporation into foods and beverages formulations has been very challenging.

LIPOPHYTOL® is a water dispersible form of plant sterols offered by LIPOFOODS which has been microencapsulated to facilitate their incorporation in food matrices. LIPOPHYTOL® unique delivery system has shown to increase phytosterols dispersibility in foods and beverages, thus providing a convenient way of introducing soy phytosterols into the human diet, avoiding the consumption of additional fat. 

In a new clinical study, whether the microencapsulation technology applied to phytosterols (LIPOPHYTOL®) modifies the activity of these bioactive compounds in comparison to raw phytosterols was further studied. For this purpose, an in vivo study was performed by the Technological Center of Nutrition and Health (CTNS1) on diet-induced combined dyslipidemia using the Golden Syrian hamster as the pre-clinical model. Serum triglycerides respect to the SV (normal diet) group on days 0, 15 and 40 after treatments with either LIPOPHYTOL® or raw phytosterols in hamsters fed high fat (HV) diet were determined:

(1) Located in Reus, Catalonia (Spain).

Results of this study showed that LIPOPHYTOL^® is more effective decreasing the hypertriglyceridemia than raw phytosterols under a high fat diet, demonstrating microencapsulation technology might enhance the activity of phytosterols.

A NEW JOINT HEALTH CLINICAL STUDY published in the PubMed listed, Elsevier publication, Asian Journal of Pharmaceutical and Clinical Research, shows Natreon’s AyuFlex® (standardized aqueous extract of Terminalia chebula) can significantly improve joint discomfort.

New Brunswick – Natreon’s AyuFlex®, a clinically studied and standardized aqueous extract of Terminalia chebula, significantly improves joint discomfort according to a human clinical study just published in The Asian Journal of Pharmaceutical and Clinical Research. AyuFlex® is a GRAS-affirmed and patented ingredient for joint health and pain relief. Osteoarthritis (OA) is one of the most common forms of arthritis and is the leading cause of disability in American adults. It is a chronic condition that is known to affect weight-bearing and other moveable joints. In the United States, an estimated 27 million people older than 25 years have clinical OA. Traditionally, NSAIDs have been the mainstay of treatment for acute and chronic pain conditions, including osteoarthritis. However, the risks of gastrointestinal toxicity and renal impairment have led to the search for alternative analgesics with fewer adverse effects, such as Terminalia chebula.

In this randomized, double blind, placebo controlled study, a total of 100 healthy human volunteers suffering from joint discomfort for at least 6 months were randomized into five treatment groups: AyuFlex® 500 mg twice daily, AyuFlex® 500 mg twice daily + Proprietary Chromium Complex (PCC) 400 μg once daily, PCC 400 μg once daily alone, placebo, and AyuFlex® 250 mg twice daily for 12 weeks. Proprietary Chromium Complex (PCC) was added to the study because in a previous clinical study at Murray State University in Kentucky, this compound significantly improved joint discomfort in dogs, and its efficacy in humans needed to to be evaluated. Assessment of symptoms of knee joint pain and discomfort was done by modified Western Ontario and McMaster Universities Arthritis Index (mWOMAC) and knee swelling index (KSI). Visual analog scale (VAS) was also used for subjective assessment of pain, stiffness, and disability. Results from this study showed that treatment with AyuFlex® 500 mg twice daily for 12 weeks resulted in significant improvements in mWOMAC scores compared to placebo (36% reduction vs. 4.52% in placebo; p < 0.001), knee swelling index ( p < 0.001 vs. placebo), and VAS pain, stiffness, and disability (p < 0.001 for all categories vs. placebo). The therapeutic benefit was evident in as short as 4 weeks. In addition, the number of rescue medications (acetaminophen) used by subjects was the least in the AyuFlex® 500 mg twice daily group. This supports the analgesic efficacy of AyuFlex®. The response seems to have a linear relationship with dose. In regards to safety, all the study medications were well tolerated and no serious adverse events were reported. No subjects dropped out of the study and all laboratory parameters were within normal limits at the end of the study. Due to its positive safety profile, and ability to improve joint discomfort, AyuFlex® may be a good choice for acute or chronic painful ailments, especially in patients who may be at higher risk for gastrointestinal or renal complications.

Natreon, Inc. is continuing its commitment to research and development with additional controlled clinical studies to evaluate the analgesic efficacy and safety of AyuFlex®.

The full study is available at: http://innovareacademics.in/journals/index.php/ajpcr/article/view/11217/5078

About Natreon Inc.
Natreon Inc. is a 17 year old company located in New Jersey with a state of the art R&D facility in Kolkata, India, and is focused on developing and marketing Ayurvedic products backed by extensive research, high degree of standardization, multiple clinical studies, safety studies, and intellectual property. Natreon’s R&D team is headed by Prof. Shibnath Ghosal, a Fulbright scholar and an eminent natural product chemist with hundreds of publications in scientific journals and a group of Ph.D. and Master’s level scientists. Natreon’s scientific research includes process optimization, development of chromatographic analytical methods such as HPLC, HPTLC, GC-MS and LC-MS for standardization, development of marker compounds, and pharmacological studies. Safety studies are done in the USA and clinical studies are conducted in reputed institutes in India as well as the USA.
For more information on AyuFlex® and Natreon’s other patented ingredients, please visit Natreon.

CARLSBAD, CA – Compound Solutions, Inc., exclusive global distributor of patent-pending TeaCrine®, today announced the results of a newly published clinical study, “A Two-Part Approach to Examine the Effects of Theacrine (TeaCrine®) Supplementation on Oxygen Consumption, Hemodynamic Responses, and Subjective Measures of Cognitive and Psychometric Parameters.” The study was published in the peer-reviewed Journal of Dietary Supplements. Preliminary data from this 2-part human clinical trial was initially presented at the Annual Conference of the International Society of Sports Nutrition in 2014.

The study outcomes highlight TeaCrine®’s unique experiential delivery that sets it apart from other energy and focus ingredient options. This branded blockbuster ingredient differentiates itself from several competitors due to its potent effects on decreasing ratings of anxiety and irritability coupled with its significant increases in energy, focus and concentration. These benefits are particularly noteworthy considering TeaCrine® does not cause increases in heart rate or blood pressure.

“We are excited that the findings reported in the Journal of Dietary Supplements study underscore what we’ve always known about TeaCrine®’s incredible benefits,” said Matthew Titlow, CEO of Compound Solutions. “We are dedicated to pushing the forefront of TeaCrine®’s applications to deliver maximum human cognitive and physical performance through further scientific exploration.”

One of the unique aspects of this ingredient is its foundation in research. For the past several years, TeaCrine® has invested in a clinical R&D fund to continually bolster and elevate the scientific evidence base underpinning the ingredient. In addition to the two seminal human studies published recently, there are two more studies underway. The first is a pharmacokinetic investigation with 50 subjects to assess the absorption, metabolism and excretion of TeaCrine® in blood. This study will also provide further substantiation of the findings on energy, focus, mood and cognitive measures observed in the Journal of Dietary Supplements study just published.

The second study will utilize more than 30 elite college athletes to examine how TeaCrine® alone, or in combination with caffeine, affects exercise and cognitive performance such as work capacity, stamina, reaction time, attention, focus and decision-making at rest and under conditions of fatigue. Both of these studies will solidify and broaden the understanding of TeaCrine® in the sports nutrition category, and provide important crossover applications in cognitive performance, and work productivity to maximize overall human potential.



About Compound Solutions, Inc.
Compound Solutions, Inc. is the go-to company representing and distributing unique, patented nutraceutical ingredients for the sports nutrition, functional food and beverage and nutritional supplement markets. Compound Solutions is the exclusive global supplier of TeaCrine®.

Gnosis is proud to announce that its commitment to providing innovative solutions to global well-being and health care challenges has been rewarded at NutraIngredients Award 2016, winning  in the FINISHED PRODUCT OF THE YEAR  – medical food category with XaQuil™ XR  from XYMOGEN, a new finished product formulated with Quatrefolic^®.

At Vitafoods, NutraIngredients Awards 2016 celebrated innovation and research of the global nutritional industry, awarding companies and products that, by seizing the most recent compelling nutritional needs, really bring tangible benefits to humans well-being.

XaQuil™ XR, formulated with Quatrefolic^® and developed through a fruitful partnership between XYMOGEN and Gnosis, triumphed as Finished Product of the Year in the Medical Food category.

The independent 10-person judging panel evaluated the true innovation, the validated research and the ability to recognize and fill a gap in the healthy product sector.  XaQuil™ XR by XYMOGEN is an innovative medical food formulated with Quatrefolic^®, and used as an adjunctive treatment for depression. XaQuil™ XR fulfills the emergent scientific demand that have compelled psychiatrists to consider augmenting traditional antidepressants with the medical food L-methylfolate.

Quatrefolic^® in XaQuil™ XR  is the glucosamine salt of the 5-methyltetrahydrofolate (5-MTHF), the metabolic active form of folate.

The specific & patented extended-release profile of Quatrefolic^® was chosen in order to replicate what happens into the intestine to dietary folate.

Medical food industry is expanding and is driven by the rise in aging population, the shift to enteral nutrition and a demand for personalized medicine.  XaQuil™ XR offers the most bioavailable form of reduced folate available in the market, Quatrefolic^®, the glucosamine salt of the 5-MTHF, in an innovative, orally administered, extended-release formulation.

About XaQuil^™XR
XaQuil^™XR is an innovative medical food formulated with Quatrefolic^® where the release of the active ingredients is tightly controlled for an optimization of the blood levels of 5-MTHF and can be used as an adjunctive treatment for depression.
XaQuil^™XR may constitute an effective, safe, and well tolerated medical food strategy for patients with major depressive disorder who have a partial response or no response to SSRIs (Selective Serotonin Reuptake Inhibitors).

In XaQuil^™XR Quatrefolic^® provides folate in the already biologically active form of 5-methyltetrahydrofolate, without any kind of metabolization. 5-MTHF can reach the systemic circulation and cross the blood-brain barrier, and enter straight the brain cell, for direct utilization in the folate cycle.

Gnosis and Xymogen have been working together to develop an unique extended release formulation in tablets with specific release profile of the active ingredient useful to increase the folate levels. The XaQuil^™XR formulation allows a time dependent release of the 5-MTHF in the gastroenteric system, followed by a time-dependent release of the active in the plasma. Extended-release of 5-MTHF may be crucial in partial response or no response subjects to SSRIs because normalizes the blood folate level and maximizes efficacy of XaQuil^™XR.

XaQuil^™XR. extended-release coating technology is property of Gnosis S.p.A (International Application PCT/IB2014/065852).

About Xymogen
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.